The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study
Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However...
Saved in:
Published in | Frontiers in microbiology Vol. 11; p. 555293 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
14.01.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the
Firmicutes/Bacteroidetes
ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of
Butyricicoccus
was increased while the abundance of
Dorea
was decreased in HFD + CUR group. Besides, some beneficial bacteria such as
Prevotella
were increased in MET-treated animals. Spearman’s correlation analysis showed that
Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_
unclassified,
Lachnospiraceae_unclassified
, and
Clostridiales_unclassified
showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both
p
< 0.05). However,
Prevotella
and
Stomatobaculum
showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD. |
---|---|
AbstractList | Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman’s correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_unclassified, Lachnospiraceae_unclassified, and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD. Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman's correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_unclassified, Lachnospiraceae_unclassified, and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD.Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman's correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_unclassified, Lachnospiraceae_unclassified, and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD. Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the Firmicutes/Bacteroidetes ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of Butyricicoccus was increased while the abundance of Dorea was decreased in HFD + CUR group. Besides, some beneficial bacteria such as Prevotella were increased in MET-treated animals. Spearman’s correlation analysis showed that Helicobacter, Akkermansia, Desulfovibrio, Romboutsia, Corynebacterium, Lactobacillus, Ruminococcaceae_ unclassified, Lachnospiraceae_unclassified , and Clostridiales_unclassified showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both p < 0.05). However, Prevotella and Stomatobaculum showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD. Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated that both curcumin (CUR) and metformin (MET) have a therapeutic effect against NAFLD and play a role in modulating the gut microbiota. However, there is a lack of direct comparison between the two medications in terms of the therapeutic efficacy and the regulatory effect on gut microbiota. In this study, we administered either CUR or MET to rats with high-fat diet (HFD)-induced obesity to observe changes in body parameters, biochemical parameters, liver, and ileum pathology and gut microbiota, and used next generation sequencing and multivariate analysis to evaluate the structural changes of gut microbiota in a NAFLD rat model before and after CUR and MET intervention. It was found that both CUR and MET attenuated hepatic ectopic fat deposition, alleviated inflammatory factors, and improved intestinal barrier integrity in HFD-fed rats. More importantly, CUR and MET reduced the ratio and reverted the composition of the HFD-disrupted gut microbiota. Both CUR and MET treatments effectively modified the gut microbiome, enriched the abundance of beneficial bacteria and reduced opportunistic pathogens in obese rats. The abundance of was increased while the abundance of was decreased in HFD + CUR group. Besides, some beneficial bacteria such as were increased in MET-treated animals. Spearman's correlation analysis showed that unclassified, , and showed significantly positive correlations with TG, TC, LDL-C, GLU, IL-6, IL-1β, and TNF-α, and negative correlations with HDL-C (both < 0.05). However, and showed an opposite trend. In summary, CUR and MET showed similar effects in alleviating hepatic steatosis, improving intestinal barrier integrity and modulating gut microbiota in HFD-induced obesity rats, and therefore may prove to be a novel adjunctive therapy for NAFLD. |
Author | Li, Ruifang Gao, Pengfei Bu, Shurui Yao, Yurong |
AuthorAffiliation | 2 Department of Infection, Jinshan Hospital Affiliated to Fudan University , Shanghai , China 3 Department of Traditional Chinese Medicine, Jinshan Hospital Affiliated to Fudan University , Shanghai , China 1 Department of Gastroenterology, Jinshan Hospital Affiliated to Fudan University , Shanghai , China |
AuthorAffiliation_xml | – name: 1 Department of Gastroenterology, Jinshan Hospital Affiliated to Fudan University , Shanghai , China – name: 3 Department of Traditional Chinese Medicine, Jinshan Hospital Affiliated to Fudan University , Shanghai , China – name: 2 Department of Infection, Jinshan Hospital Affiliated to Fudan University , Shanghai , China |
Author_xml | – sequence: 1 givenname: Ruifang surname: Li fullname: Li, Ruifang – sequence: 2 givenname: Yurong surname: Yao fullname: Yao, Yurong – sequence: 3 givenname: Pengfei surname: Gao fullname: Gao, Pengfei – sequence: 4 givenname: Shurui surname: Bu fullname: Bu, Shurui |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33584555$$D View this record in MEDLINE/PubMed |
BookMark | eNp9UstuEzEUtVARLaUfwAZ5ySapH-MZDwukKPQlJSBBkdhZHj9SVzPj4Eek_D2eplQtCyxbfp1zrq_veQuORj8aAN5jNKeUt-d2cKqbE0TQnDFGWvoKnOC6rmYUkV9Hz9bH4CzGe1RaVcAIvQHHlDJeFdYJ2N3eGVhGkFuTk1PwwlqnpNpDb-EyB5UHN8JdnMO1SdaHaVf62uvcy-TGDUxF4ConuHYq-M75JCfA18Xl6gv8LlP8BBdw6YetDAW_M_BHynr_Dry2so_m7HE-BT8vL26X17PVt6ub5WI1U4ziNGMEaYpoXVuGtakI00jXpOTKGsSk6jqjSh66xp3hXWtJQ3glGZnICBFM6Cm4OehqL-_FNrhBhr3w0omHAx82QoaSdm-ExpJRZBgnLSkiWqq6w5zyTtZGW6uL1ueD1jZ3g9HKjCnI_oXoy5vR3YmN34mGNxVpWBH4-CgQ_O9sYhKDi8r0vRyNz1GQiresZYzXBfrheaynIH8LVwD4ACifHmMw9gmCkZj8IR78ISZ_iIM_Cqf5h6NcKkXx03Nd_x_mHxQAwGs |
CitedBy_id | crossref_primary_10_1007_s00774_021_01247_w crossref_primary_10_3389_fnut_2022_960309 crossref_primary_10_3390_toxins14120859 crossref_primary_10_1111_jcmm_17631 crossref_primary_10_1080_10408398_2023_2204349 crossref_primary_10_3390_ani13223575 crossref_primary_10_18632_aging_203821 crossref_primary_10_3390_nu15030743 crossref_primary_10_3390_ani14081223 crossref_primary_10_3389_fmicb_2023_1274559 crossref_primary_10_1016_j_phrs_2023_106679 crossref_primary_10_3389_fmicb_2022_925929 crossref_primary_10_3390_ijms24054603 crossref_primary_10_1093_femsle_fnad016 crossref_primary_10_3389_fcvm_2022_972603 crossref_primary_10_1039_D4FO01813C crossref_primary_10_1515_tjb_2024_0027 crossref_primary_10_3390_ijms25147710 crossref_primary_10_3389_fcimb_2024_1323261 crossref_primary_10_3389_fphar_2023_1163694 crossref_primary_10_3390_nu16162644 crossref_primary_10_1002_ptr_7681 crossref_primary_10_1089_met_2022_0105 crossref_primary_10_3390_microorganisms10071281 crossref_primary_10_1002_fsn3_4178 crossref_primary_10_1039_D1FO02481G crossref_primary_10_3389_fmicb_2022_1051200 crossref_primary_10_1016_j_foodchem_2024_140514 crossref_primary_10_3389_fphar_2024_1343193 crossref_primary_10_3390_nu13093289 crossref_primary_10_3390_nu15081989 crossref_primary_10_26599_FSHW_2022_9250218 crossref_primary_10_3390_nu15245053 crossref_primary_10_1007_s00210_023_02520_7 crossref_primary_10_1007_s12029_022_00809_z |
Cites_doi | 10.1126/science.1241165 10.1038/s41598-019-38874-3 10.1016/j.bbagen.2017.03.017 10.1038/s41591-018-0222-4 10.1152/ajpendo.00285.2017 10.1038/nature11450 10.1002/hep.28431 10.1016/j.cell.2014.05.052 10.1136/gut.2010.215665 10.1002/hep.26225 10.1038/s41366-018-0290-z 10.1111/j.1365-2672.1991.tb02739.x 10.3390/ijms19103075 10.1371/journal.pone.0020944 10.3390/nu9101124 10.1007/s00535-017-1415-1 10.1053/gast.1996.v110.pm8964397 10.1136/gutjnl-2019-319726 10.1128/aem.01541-9 10.1038/nrgastro.2017.109 10.1038/srep14405 10.1586/17474124.2015.1051029 10.1038/nrgastro.2016.85 10.1016/j.biopha.2019.109131 10.1007/s00125-017-4342-z 10.1007/s10620-016-4045-1 10.1017/s0007114519001508 10.3390/md17080455 10.1136/gutjnl-2012-303839 10.1016/j.metabol.2017.12.009 10.5152/tjg.2017.17033 10.1152/ajpendo.00107.2017 10.1038/ismej.2014.177 10.4254/wjh.v7.i12.1679 10.1093/bioinformatics/btr507 10.1021/acs.jafc.9b00249 10.1016/j.arteri.2018.03.004 10.4254/wjh.v11.i8.619 10.1155/2018/7261619 10.1155/2018/9734845 10.1002/mnfr.200500013 10.3390/nu11112642 10.1016/j.ctim.2020.102322 10.1039/c7fo01346a 10.1002/hep.26093 10.1038/s41598-019-49462-w 10.1038/nature08530 10.1042/cs20080253 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Li, Yao, Gao and Bu. Copyright © 2021 Li, Yao, Gao and Bu. 2021 Li, Yao, Gao and Bu |
Copyright_xml | – notice: Copyright © 2021 Li, Yao, Gao and Bu. – notice: Copyright © 2021 Li, Yao, Gao and Bu. 2021 Li, Yao, Gao and Bu |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fmicb.2020.555293 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-302X |
ExternalDocumentID | oai_doaj_org_article_d1a530e582924a5dac6b1838ba6edffd PMC7874275 33584555 10_3389_fmicb_2020_555293 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Science and Technology Commission of Shanghai Municipality |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK ECGQY GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 PGMZT RNS RPM IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c531t-520d30366f51de425d0d622935705acbbec845d61be8b9f27284a52c531002123 |
IEDL.DBID | M48 |
ISSN | 1664-302X |
IngestDate | Wed Aug 27 01:30:45 EDT 2025 Thu Aug 21 18:18:23 EDT 2025 Fri Jul 11 16:12:19 EDT 2025 Mon Jul 21 06:06:51 EDT 2025 Thu Apr 24 22:51:19 EDT 2025 Tue Jul 01 01:12:52 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | metformin non-alcoholic fatty liver disease short-chain fatty acids gut microbiota curcumin |
Language | English |
License | Copyright © 2021 Li, Yao, Gao and Bu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c531t-520d30366f51de425d0d622935705acbbec845d61be8b9f27284a52c531002123 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Gislane Lelis Vilela de Oliveira, São Paulo State University, Brazil; Hein Min Tun, The University of Hong Kong, Hong Kong This article was submitted to Systems Microbiology, a section of the journal Frontiers in Microbiology Edited by: Koichi Tamano, National Institute of Advanced Industrial Science and Technology (AIST), Japan |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmicb.2020.555293 |
PMID | 33584555 |
PQID | 2489595586 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d1a530e582924a5dac6b1838ba6edffd pubmedcentral_primary_oai_pubmedcentral_nih_gov_7874275 proquest_miscellaneous_2489595586 pubmed_primary_33584555 crossref_primary_10_3389_fmicb_2020_555293 crossref_citationtrail_10_3389_fmicb_2020_555293 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-01-14 |
PublicationDateYYYYMMDD | 2021-01-14 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in microbiology |
PublicationTitleAlternate | Front Microbiol |
PublicationYear | 2021 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Hu (B15) 2019; 17 Li (B19) 2018; 19 Lin (B20) 2019; 67 Qin (B30) 2012; 490 Jin (B16) 2018; 314 Cummings (B8) 1991; 70 Leung (B18) 2016; 13 Neyrinck (B27) 2011; 6 Saberi-Karimian (B33) 2020; 49 Younossi (B44) 2016; 64 Smith (B36) 2013; 341 Younossi (B43) 2018; 15 Zhang (B46) 2019; 118 Byrne (B4) 2009; 116 Maslowski (B23) 2009; 461 Mathur (B24) 2015; 9 Cox (B7) 2014; 158 Tang (B39) 2018; 2018 Zeng (B45) 2019; 9 Ferguson (B11) 2018; 82 Ma (B21) 2017; 9 Carrera-Quintanar (B5) 2018; 2018 Murphy (B26) 2010; 59 Zhang (B47) 2015; 5 Chen (B6) 2018; 9 Sun (B38) 2018; 24 Xu (B42) 2015; 9 Galvez (B13) 2005; 49 Magoč (B22) 2011; 27 Granado-Serrano (B14) 2019; 9 Rodriguez (B32) 2020; 69 Karvonen (B17) 2019; 43 Feng (B10) 2017; 1861 Velazquez (B41) 2019; 11 Meroni (B25) 2019; 11 Schloss (B34) 2009; 75 Rena (B31) 2017; 60 Bechmann (B3) 2013; 57 Abdou (B1) 2016; 61 Sumida (B37) 2018; 53 D’Argenio (B9) 1996; 110 Zhu (B48) 2013; 57 Fontané (B12) 2018; 30 Niu (B28) 2019; 122 Özkul (B29) 2017; 28 Shin (B35) 2014; 63 Van Hul (B40) 2018; 314 Abdul-Hai (B2) 2015; 7 |
References_xml | – volume: 341 start-page: 569 year: 2013 ident: B36 article-title: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. publication-title: Science doi: 10.1126/science.1241165 – volume: 9 year: 2019 ident: B14 article-title: Faecal bacterial and short-chain fatty acids signature in hypercholesterolemia. publication-title: Sci. Rep. doi: 10.1038/s41598-019-38874-3 – volume: 1861 start-page: 1801 year: 2017 ident: B10 article-title: Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbagen.2017.03.017 – volume: 24 start-page: 1919 year: 2018 ident: B38 article-title: Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. publication-title: Nat. Med. doi: 10.1038/s41591-018-0222-4 – volume: 314 start-page: E201 year: 2018 ident: B16 article-title: Curcumin and other dietary polyphenols: potential mechanisms of metabolic actions and therapy for diabetes and obesity. publication-title: Am. J. Physiol. Endocrinol. Metab. doi: 10.1152/ajpendo.00285.2017 – volume: 490 start-page: 55 year: 2012 ident: B30 article-title: A metagenome-wide association study of gut microbiota in type 2 diabetes. publication-title: Nature doi: 10.1038/nature11450 – volume: 64 start-page: 73 year: 2016 ident: B44 article-title: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. publication-title: Hepatology doi: 10.1002/hep.28431 – volume: 158 start-page: 705 year: 2014 ident: B7 article-title: Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. publication-title: Cell doi: 10.1016/j.cell.2014.05.052 – volume: 59 start-page: 1635 year: 2010 ident: B26 article-title: Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. publication-title: Gut doi: 10.1136/gut.2010.215665 – volume: 57 start-page: 1394 year: 2013 ident: B3 article-title: Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. publication-title: Hepatology doi: 10.1002/hep.26225 – volume: 43 start-page: 713 year: 2019 ident: B17 article-title: Gut microbiota and overweight in 3-year old children. publication-title: Int. J. Obes. doi: 10.1038/s41366-018-0290-z – volume: 70 start-page: 443 year: 1991 ident: B8 article-title: The control and consequences of bacterial fermentation in the human colon. publication-title: J. Appl. Bacteriol. doi: 10.1111/j.1365-2672.1991.tb02739.x – volume: 19 year: 2018 ident: B19 article-title: Regulatory efficacy of the polyunsaturated fatty acids from microalgae spirulina platensis on lipid metabolism and gut microbiota in high-fat diet rats. publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms19103075 – volume: 6 year: 2011 ident: B27 article-title: Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. publication-title: PLoS One doi: 10.1371/journal.pone.0020944 – volume: 9 year: 2017 ident: B21 article-title: Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy. publication-title: Nutrients doi: 10.3390/nu9101124 – volume: 53 start-page: 362 year: 2018 ident: B37 article-title: Current and future pharmacological therapies for NAFLD/NASH. publication-title: J. Gastroenterol. doi: 10.1007/s00535-017-1415-1 – volume: 110 start-page: 1727 year: 1996 ident: B9 article-title: Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. publication-title: Gastroenterology doi: 10.1053/gast.1996.v110.pm8964397 – volume: 69 start-page: 1975 year: 2020 ident: B32 article-title: Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients. publication-title: Gut doi: 10.1136/gutjnl-2019-319726 – volume: 75 start-page: 7537 year: 2009 ident: B34 article-title: Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. publication-title: Appl. Environ. Microbiol. doi: 10.1128/aem.01541-9 – volume: 15 start-page: 11 year: 2018 ident: B43 article-title: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/nrgastro.2017.109 – volume: 5 year: 2015 ident: B47 article-title: Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. publication-title: Sci. Rep. doi: 10.1038/srep14405 – volume: 9 start-page: 1087 year: 2015 ident: B24 article-title: Obesity and the microbiome. publication-title: Expert. Rev. Gastroenterol. Hepatol. doi: 10.1586/17474124.2015.1051029 – volume: 13 start-page: 412 year: 2016 ident: B18 article-title: The role of the gut microbiota in NAFLD. publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/nrgastro.2016.85 – volume: 118 year: 2019 ident: B46 article-title: Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice. publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2019.109131 – volume: 60 start-page: 1577 year: 2017 ident: B31 article-title: The mechanisms of action of metformin. publication-title: Diabetologia doi: 10.1007/s00125-017-4342-z – volume: 61 start-page: 1268 year: 2016 ident: B1 article-title: Gut Microbiota of nonalcoholic fatty liver disease. publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-016-4045-1 – volume: 122 start-page: 616 year: 2019 ident: B28 article-title: Curcumin attenuates insulin resistance and hepatic lipid accumulation in a rat model of intra-uterine growth restriction through insulin signalling pathway and sterol regulatory element binding proteins. publication-title: Br. J. Nutr. doi: 10.1017/s0007114519001508 – volume: 17 year: 2019 ident: B15 article-title: Long-chain bases from sea cucumber alleviate obesity by modulating gut microbiota. publication-title: Mar. Drugs doi: 10.3390/md17080455 – volume: 63 start-page: 727 year: 2014 ident: B35 article-title: An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. publication-title: Gut doi: 10.1136/gutjnl-2012-303839 – volume: 82 start-page: 22 year: 2018 ident: B11 article-title: Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial. publication-title: Metabolism doi: 10.1016/j.metabol.2017.12.009 – volume: 28 start-page: 361 year: 2017 ident: B29 article-title: Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis. publication-title: Turk J. Gastroenterol. doi: 10.5152/tjg.2017.17033 – volume: 314 start-page: E334 year: 2018 ident: B40 article-title: Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier. publication-title: Am. J. Physiol. Endocrinol. Metab. doi: 10.1152/ajpendo.00107.2017 – volume: 9 start-page: 552 year: 2015 ident: B42 article-title: Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. publication-title: ISME J. doi: 10.1038/ismej.2014.177 – volume: 7 start-page: 1679 year: 2015 ident: B2 article-title: Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. publication-title: World J. Hepatol. doi: 10.4254/wjh.v7.i12.1679 – volume: 27 start-page: 2957 year: 2011 ident: B22 article-title: FLASH: fast length adjustment of short reads to improve genome assemblies. publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr507 – volume: 67 start-page: 3624 year: 2019 ident: B20 article-title: Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat model. publication-title: J. Agric. Food Chem. doi: 10.1021/acs.jafc.9b00249 – volume: 30 start-page: 271 year: 2018 ident: B12 article-title: Influence of the microbiota and probiotics in obesity. publication-title: Clin. Investig. Arterioscler. doi: 10.1016/j.arteri.2018.03.004 – volume: 11 start-page: 619 year: 2019 ident: B41 article-title: Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. publication-title: World J. Hepatol. doi: 10.4254/wjh.v11.i8.619 – volume: 2018 year: 2018 ident: B39 article-title: Modulation of the gut microbiota in rats by hugan qingzhi tablets during the treatment of high-fat-diet-induced nonalcoholic fatty liver Disease. publication-title: Oxid. Med. Cell Longev. doi: 10.1155/2018/7261619 – volume: 2018 year: 2018 ident: B5 article-title: Phytochemicals that influence gut microbiota as prophylactics and for the treatment of obesity and inflammatory diseases. publication-title: Mediators Inflamm. doi: 10.1155/2018/9734845 – volume: 49 start-page: 601 year: 2005 ident: B13 article-title: Effects of dietary fiber on inflammatory bowel disease. publication-title: Mol. Nutr. Food Res. doi: 10.1002/mnfr.200500013 – volume: 11 year: 2019 ident: B25 article-title: The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. publication-title: Nutrients doi: 10.3390/nu11112642 – volume: 49 year: 2020 ident: B33 article-title: Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: a randomized controlled trial. publication-title: Complement. Ther. Med. doi: 10.1016/j.ctim.2020.102322 – volume: 9 start-page: 3732 year: 2018 ident: B6 article-title: Modulation of gut microbiota by mulberry fruit polysaccharide treatment of obese diabetic db/db mice. publication-title: Food Funct. doi: 10.1039/c7fo01346a – volume: 57 start-page: 601 year: 2013 ident: B48 article-title: Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. publication-title: Hepatology doi: 10.1002/hep.26093 – volume: 9 year: 2019 ident: B45 article-title: Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities. publication-title: Sci. Rep. doi: 10.1038/s41598-019-49462-w – volume: 461 start-page: 1282 year: 2009 ident: B23 article-title: Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. publication-title: Nature doi: 10.1038/nature08530 – volume: 116 start-page: 539 year: 2009 ident: B4 article-title: Metabolic disturbances in non-alcoholic fatty liver disease. publication-title: Clin. Sci. doi: 10.1042/cs20080253 |
SSID | ssj0000402000 |
Score | 2.4738944 |
Snippet | Structural disruption of gut microbiota is closely related to the occurrence of non-alcoholic fatty liver disease (NAFLD). Previous research has demonstrated... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 555293 |
SubjectTerms | curcumin gut microbiota metformin Microbiology non-alcoholic fatty liver disease short-chain fatty acids |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlEOil9F33EVToqeDUli1Z7m2zyTaUbg4lgdzE6OF2IfWWrB3Yf98Z2dnsltJeCr7YluzB34xmBo2_Yexd3uSFr3VIK2UxQQFrU3BOpspBDU4JLyJZ9fxMnV6Uny_l5VarL6oJG-iBhw_3wecgiyxILTBTAOnxARbVUFtQwTeNp9UXfd5WMhXXYEqLsnEbE7OwGmFaOIv5oMgOpZSiLnYcUeTr_1OQ-Xut5JbzmT1kD8aokU8GaR-xe6F9zPaHPpLrJ-wGwebnd39S8RMihgC35suGT_tr1_9YtPxmdcjnoaMoFc_wmC99bN7VfuMYBvJPfcfni4GYqQMacDaZfTnmX6FbfeQTPr0jCudUfrh-yi5mJ-fT03RsqJA6NLUOk87Mk8tSjcx9QGv1mVcIRiGrTIKziKcupVe5DdrWjajQd4EUNDlSwRfP2F67bMMLxtHNBygo4tNQNlUFUADNwujMK-3LhGW3X9e4kW2cml5cGcw6CBATATEEiBkASdj7zZSfA9XG3wYfEWSbgcSSHS-g7phRd8y_dCdhb28BN2hVtFUCbVj2KyNKXctaSq0S9nxQgM2rigKDNpQiYdWOauzIsnunXXyPzN24Opaiki__h_Cv2H1B9TVZnubla7bXXffhDQZInT2ItvALjnkPmQ priority: 102 providerName: Directory of Open Access Journals |
Title | The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33584555 https://www.proquest.com/docview/2489595586 https://pubmed.ncbi.nlm.nih.gov/PMC7874275 https://doaj.org/article/d1a530e582924a5dac6b1838ba6edffd |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBZdx2AvY_d5l6LBngYOtmzJ8mCMLGtaxtyH0UDejG7uAp3dJnZZ_v3OkZ10GWEMQiCOZBl_5-h8x5K_Q8i7uIoTm0sXZkJDgqK0DpUxPBRG5coIZpkXqy7OxOks_Trn8wOyKW813MDV3tQO60nNlpejX9frT-DwHzHjhHgLCCyMhlSPRSPOOcSvO-QuBKYMCxoUA9v3EzPmSv6llFgIXA9g836dc_9ZdiKVF_Tfx0L_3kz5R3SaPiQPBlpJx70dPCIHrn5M7vWFJtdPyA1YAz2_fdWKHqNyhDJr2lR00i1N93NR05vViBauRRoLv-BTNNZX96ovKPBEetK1tFj0yk2twgZn4-m3L_S7alcf6JhObpXEKe5PXD8ls-nx-eQ0HCouhAZ8sYWsNLIY00TFY-vAnW1kBaCV8CziymgAXKbcilg7qfOKZRDcFGfY2WvFJ8_IYd3U7gWhwAOcSpASSpVWWaZUorAX0DcrpE0DEm3ubmkGOXKsinFZQlqCgJQekBIBKXtAAvJ-2-Wq1-L4V-PPCNm2Icpo-wPN8qIcvLK0seJJ5LhkkIYqbsE6NcxxUivhbFXZgLzdAF6C2-Faiqpd061Klsqc55xLEZDnvQFsh0oSYHVwFQHJdkxj51p2_6kXP7y0N0yfKcv4y_8Y9xW5z3B_TRSHcfqaHLbLzr0BgtTqI_9gAb5P5vGRd4HfkQcPsQ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Therapeutic+Efficacy+of+Curcumin+vs.+Metformin+in+Modulating+the+Gut+Microbiota+in+NAFLD+Rats%3A+A+Comparative+Study&rft.jtitle=Frontiers+in+microbiology&rft.au=Li%2C+Ruifang&rft.au=Yao%2C+Yurong&rft.au=Gao%2C+Pengfei&rft.au=Bu%2C+Shurui&rft.date=2021-01-14&rft.issn=1664-302X&rft.eissn=1664-302X&rft.volume=11&rft.spage=555293&rft_id=info:doi/10.3389%2Ffmicb.2020.555293&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-302X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-302X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-302X&client=summon |